/CRDF

Cardiff Oncology Inc

CRDF

$1.21USD↑+0.00%+0.00 today

MARKET CAP

94.1M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$1 – $1

52W RANGE

$1

$3

AI Summary

Stalk

TrimMedium

CRDF remains in Stage 4 decline with medium-term bearish bias—execution should focus on trimming into rallies around the declining 9/21 EMA zone and prior consolidation highs. Short-term timing is neutral amid extreme oversold conditions, suggesting deferred engagement until relief bounces stall.

↑Onvansertib shows 64% ORR in 30 mg cohort vs 33% in control arm.
↑Strategic shift to first-line RAS-mutated mCRC backed by FDA guidance.
↓Q4 cash burn of ~$10.3M per quarter strains the $91.7M runway.

Full analysis →

Buying

3

institutions

Selling

5

institutions

New Positions

1

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	SELL	972.87 K	1.26 M	+-3.01 M	-80.4%	0.00%
AC Aqr Capital Management LLC Q2 2026	BUY	346.35 K	450.26 K	+280.20 K	+320.1%	0.00%
CA Citadel Advisors LLC Q2 2026	SELL	197.40 K	256.62 K	+-157.17 K	-55.3%	0.00%
MM Millennium Management LLC Q2 2026	BUY	134.52 K	174.87 K	+111.49 K	+368.7%	0.00%
PA Point72 Asset Management, L.P. Q2 2026	BUYNEW	28.39 K	36.90 K	+28.39 K	+0.0%	0.00%
RC Rockefeller Capital Management L.P. Q2 2026	SELL	20.00 K	26.00 K	+-36.50 K	-71.6%	0.00%
RT Renaissance Technologies LLC Q2 2026	SELL	13.94 K	18.12 K	+-87.31 K	-89.0%	0.00%
JC Jpmorgan Chase & Co Q2 2026	SELL	1.92 K	2.43 K	+-24.81 K	-94.1%	0.00%